Joseph Gilliam - Glaukos Corp President
| GKOS Stock | USD 140.83 0.61 0.43% |
President
Mr. Joseph E. Gilliam was appointed as Chief Financial Officer, Senior Vice President Corporationrationrate Development of the Company, Mr. Gilliam has served as our chief financial officer and senior vice president, corporate development since May 2017. He has nearly 20 years of experience across capital markets, strategic advisory, finance and banking services with an emphasis on the life sciences industry, including the medical technology, diagnostics and biotechnology sectors. From 2013 to May 2017, he was a Managing Director in the Healthcare Investment Banking group at J.P. Morgan, where he led the Glaukos initial public offering for the firm. From 2001 to 2013, Mr. Gilliam held increasingly responsible positions at J.P. Morgan, with experience spanning mergers and acquisitions, primary and secondary public equity offerings, bank lending, bond offerings and other transactions. His prior experience includes positions at The Beacon Group and PricewaterhouseCoopers since 2022.
| Age | 48 |
| Tenure | 2 years |
| Address | One Glaukos Way, Aliso Viejo, CA, United States, 92656 |
| Phone | 949 367 9600 |
| Web | https://www.glaukos.com |
Joseph Gilliam Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Gilliam against Glaukos Corp stock is an integral part of due diligence when investing in Glaukos Corp. Joseph Gilliam insider activity provides valuable insight into whether Glaukos Corp is net buyers or sellers over its current business cycle. Note, Glaukos Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Glaukos Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Gilliam over a week ago Acquisition by Joseph Gilliam of 200 shares of Glaukos Corp at 55.18 subject to Rule 16b-3 | ||
Joseph Gilliam over three months ago Disposition of 2500 shares by Joseph Gilliam of Glaukos Corp at 55.18 subject to Rule 16b-3 | ||
Joseph Gilliam over three months ago Disposition of 200 shares by Joseph Gilliam of Glaukos Corp at 96.61 subject to Rule 16b-3 |
Glaukos Corp Management Efficiency
The company has return on total asset (ROA) of (0.0774) % which means that it has lost $0.0774 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.261) %, meaning that it created substantial loss on money invested by shareholders. Glaukos Corp's management efficiency ratios could be used to measure how well Glaukos Corp manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.24 in 2024. Return On Capital Employed is likely to drop to -0.16 in 2024. At this time, Glaukos Corp's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 22.4 M in 2024, whereas Other Assets are likely to drop slightly above 15.3 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Ryan Miller | LivaNova PLC | N/A | |
| Joel Becker | Integer Holdings Corp | 53 | |
| Stanley III | CONMED | 49 | |
| Gregory Odle | Orthopediatrics Corp | 54 | |
| Tyler Lipschultz | Orthofix Medical | 57 | |
| David Bailey | Orthopediatrics Corp | 45 | |
| Jennifer Bolt | Integer Holdings Corp | 55 | |
| Paul Buckman | LivaNova PLC | 68 | |
| Anthony Borowicz | Integer Holdings Corp | 67 | |
| Daniel Gerritzen | Orthopediatrics Corp | 54 | |
| Patrick Beyer | CONMED | 58 | |
| Jim Stephens | Integer Holdings Corp | 50 | |
| Juergen Srega | Bruker | 69 | |
| Heather Cohen | CONMED | 51 | |
| Peter Shagory | CONMED | 55 | |
| Franco Poletti | LivaNova PLC | N/A | |
| John Kennedy | CONMED | 66 | |
| Kimberley Elting | Orthofix Medical | 59 | |
| Kirk Thor | Integer Holdings Corp | 60 | |
| Johonna Pelletier | CONMED | 51 | |
| Tom Thomas | Integer Holdings Corp | 53 | |
Management Performance
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0774 |
Glaukos Corp Leadership Team
Elected by the shareholders, the Glaukos Corp's board of directors comprises two types of representatives: Glaukos Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Glaukos. The board's role is to monitor Glaukos Corp's management team and ensure that shareholders' interests are well served. Glaukos Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Glaukos Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mory Gharib, CoFounder | ||
| Gilbert Kliman, Independent Director | ||
| Michele Allegretto, Senior Resources | ||
| Leana Wen, Independent Director | ||
| L Katz, Chief Medical Officer | ||
| Thomas Burns, Chairman of the Board, President, Chief Executive Officer | ||
| Robert Davis, General VP | ||
| Diane Biagianti, Sr Counsel | ||
| David Hoffmeister, Independent Director | ||
| David Haffner, VP Technologies | ||
| Mark Foley, Lead Independent Director | ||
| Denice Torres, Independent Director | ||
| William Link, Independent Chairman of the Board | ||
| Chris Calcaterra, Chief Commercial Officer | ||
| Joseph Gilliam, Chief Financial Officer, Senior Vice President - Corporate Development | ||
| Christopher Lewis, Vice Affairs | ||
| Diana Scherer, VP Counsel | ||
| Alex Thurman, Chief Financial Officer, Senior Vice President | ||
| Tomas Navratil, Chief Development Officer | ||
| MD FACS, Chief Officer | ||
| Jane Rady, Senior Development | ||
| Aimee Weisner, Independent Director | ||
| Robert JD, General VP | ||
| Marc Stapley, Independent Director |
Glaukos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Glaukos Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.0774 | ||||
| Profit Margin | (0.42) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 7.69 B | ||||
| Shares Outstanding | 55.14 M | ||||
| Shares Owned By Insiders | 3.19 % | ||||
| Shares Owned By Institutions | 96.81 % | ||||
| Number Of Shares Shorted | 2.64 M | ||||
| Price To Earning | 94.70 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Glaukos Stock Analysis
When running Glaukos Corp's price analysis, check to measure Glaukos Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Glaukos Corp is operating at the current time. Most of Glaukos Corp's value examination focuses on studying past and present price action to predict the probability of Glaukos Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Glaukos Corp's price. Additionally, you may evaluate how the addition of Glaukos Corp to your portfolios can decrease your overall portfolio volatility.